These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 30101)

  • 41. Patterns of response to neuroleptic treatment: factors influencing the amelioration of individual symptoms in psychotic patients.
    Axelsson R; Ohman R
    Acta Psychiatr Scand; 1987 Dec; 76(6):707-14. PubMed ID: 3442262
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Naloxone effects on manic symptoms and growth-hormone levels.
    Janowsky D; Judd L; Huey L; Roitman N; Parker D; Segal D
    Lancet; 1978 Aug; 2(8084):320. PubMed ID: 79114
    [No Abstract]   [Full Text] [Related]  

  • 43. Opiate antagonists for the treatment of schizophrenia.
    Welch EB; Thompson DF
    J Clin Pharm Ther; 1994 Oct; 19(5):279-83. PubMed ID: 7806598
    [TBL] [Abstract][Full Text] [Related]  

  • 44. High-dose naloxone in older normal subjects: implications for Alzheimer's disease.
    Tariot PN; Gross M; Sunderland T; Cohen MR; Weingartner H; Murphy DL; Cohen RM
    J Am Geriatr Soc; 1988 Aug; 36(8):681-6. PubMed ID: 3042841
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Naloxone-ethanol interaction in experimental and clinical situations.
    Nuotto E; Palva ES; Seppälä T
    Acta Pharmacol Toxicol (Copenh); 1984 Apr; 54(4):278-84. PubMed ID: 6375258
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Naltrexone in chronic schizophrenia. Results of a clinical trial.
    Ragheb M; Berney S; Ban T
    Int Pharmacopsychiatry; 1980; 15(1):1-5. PubMed ID: 6993401
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Design and interpretation of opiate antagonist trials in dementia.
    Tariot PN; Sunderland T; Murphy DL; Cohen MR; Welkowitz JA; Weingartner H; Newhouse PA; Cohen RM
    Prog Neuropsychopharmacol Biol Psychiatry; 1986; 10(3-5):611-26. PubMed ID: 3025928
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Double blind controlled trials of cholecystokinin octapeptide in neuroleptic-refractory schizophrenia.
    Peselow E; Angrist B; Sudilovsky A; Corwin J; Siekierski J; Trent F; Rotrosen J
    Psychopharmacology (Berl); 1987; 91(1):80-4. PubMed ID: 2881320
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Naloxone attenuates the anxiolytic action of diazepam in man.
    Duka T; Millan MJ; Ulsamer B; Doenicke A
    Life Sci; 1982 Oct 18-25; 31(16-17):1833-6. PubMed ID: 7154835
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Naloxone reduces cigarette smoking.
    Karras A; Kane JM
    Life Sci; 1980 Oct; 27(17):1541-5. PubMed ID: 7003284
    [No Abstract]   [Full Text] [Related]  

  • 51. Prevention of effects of alcohol intoxication by naloxone.
    Jeffcoate WJ; Herbert M; Cullen MH; Hastings AG; Walder CP
    Lancet; 1979 Dec; 2(8153):1157-9. PubMed ID: 91889
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Naloxone in schizophrenia: negative result.
    Lipinski J; Meyer R; Kornetsky C; Cohen BM
    Lancet; 1979 Jun; 1(8129):1292-3. PubMed ID: 87747
    [No Abstract]   [Full Text] [Related]  

  • 53. Effects of naloxone on auditory hallucinations.
    Orr M; Oppenheimer C
    Br Med J; 1978 Feb; 1(6111):481. PubMed ID: 626845
    [No Abstract]   [Full Text] [Related]  

  • 54. Learning to live with hearing voices.
    Knoll E
    BMJ; 2018 May; 361():k2018. PubMed ID: 29853479
    [No Abstract]   [Full Text] [Related]  

  • 55. Naloxone does not benefit levodopa-induced hallucinations in Parkinson's disease.
    Sandyk R; Gillman MA
    Ann Neurol; 1984 Dec; 16(6):723. PubMed ID: 6524877
    [No Abstract]   [Full Text] [Related]  

  • 56. Double-blind placebo-controlled trial of naloxone on motor deficits in acute cerebrovascular disease.
    Perraro F; Tosolini G; Pertoldi F; Sbrojavacca R; Beorchia A; Bulfoni A; Del Fabbro L; Grassi L; Lestuzzi A; Mione V
    Lancet; 1984 Apr; 1(8382):915. PubMed ID: 6143225
    [No Abstract]   [Full Text] [Related]  

  • 57. Naloxone does not antagonize diazepam-induced sedation.
    Christensen KN; Hüttel M
    Anesthesiology; 1979 Aug; 51(2):187. PubMed ID: 378038
    [No Abstract]   [Full Text] [Related]  

  • 58. Negative naloxone effects on serum-prolactin.
    Janowsky D; Judd L; Huey L; Roitman N; Parker D; Segal D
    Lancet; 1978 Sep; 2(8090):637. PubMed ID: 80568
    [No Abstract]   [Full Text] [Related]  

  • 59. The effect of naloxone on pentazocine induced hallucinations.
    Jago RH; Restall J; Stonham J
    J R Army Med Corps; 1984 Feb; 130(1):64-5. PubMed ID: 6716360
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Naloxone is not an effective antagonist of ethanol.
    Mattila MJ; Nuotto E; Seppälä T
    Lancet; 1981 Apr; 1(8223):775-6. PubMed ID: 6110971
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.